Nephromag (Buffered Phosphate Solution | Mertiatide)

Mertiatide, the active ingredient in Nephromag, is a buffered phosphate solution presented as an intravenous solution for use in clinical settings. It helps correct phosphate deficits and supports acid‑base balance in patients with renal impairment or undergoing dialysis.

GNH USA supplies Nephromag as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, dialysis clinics and other healthcare facilities worldwide.

Nephromag (Mertiatide) is used to manage phosphate homeostasis in conditions associated with phosphate depletion.

- Hypophosphatemia: restores serum phosphate levels in patients with low phosphate. - Phosphate depletion during continuous renal replacement therapy: provides controlled phosphate repletion to maintain metabolic balance. - Renal osteodystrophy: assists in correcting phosphate abnormalities in chronic kidney disease.

Common Side Effects: - Hyperphosphatemia: elevated serum phosphate levels. - Hypocalcemia: reduced calcium levels due to phosphate binding. - Infusion site irritation: redness or discomfort at the injection site. - Nausea or vomiting. - Transient fever or chills. - Electrolyte imbalance: changes in potassium or magnesium.

Serious or Rare Side Effects: - Severe hyperphosphatemia leading to calcium‑phosphate precipitation. - Anaphylactic reaction: difficulty breathing, rash, swelling. - Metabolic acidosis: significant pH disturbance. - Acute renal failure worsening. - Cardiac arrhythmias associated with electrolyte shifts. - Disseminated intravascular coagulation (rare).

Nephromag should be administered under close clinical monitoring.

- Serum phosphate monitoring: check levels before and during therapy. - Calcium balance: avoid concurrent high calcium infusions to prevent precipitation. - Renal function: adjust use in patients with severe renal impairment. - Infusion rate: administer slowly to reduce risk of electrolyte shifts. - Contraindications: do not use in patients with existing hyperphosphatemia. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Potential drug interactions require careful assessment.

Major Interactions (Avoid): - Calcium-containing products: risk of calcium‑phosphate precipitation. - Vitamin D analogues: may exacerbate hypercalcemia. - High-dose phosphate binders: can lead to excessive phosphate levels.

Moderate Interactions (Monitor Closely): - Loop diuretics: increase renal phosphate excretion. - ACE inhibitors: may affect renal handling of electrolytes. - NSAIDs: can alter renal perfusion and phosphate clearance. - Antacids containing aluminum or magnesium: may interfere with phosphate absorption.